XBB.1.5适配型COVID-19 mRNA疫苗而非既往奥密克戎变异株感染可增强炎症性肠病患者对SARS-CoV-2 JN.1变异株的中和
该研究利用两个纵向队列评估炎症性肠病患者对SARS-CoV-2 JN.1变异株的免疫保护。结果显示,接种原始疫苗后多数个体缺乏JN.1中和能力,抗TNF治疗与低水平抗JN.1-RBD IgG相关;既往奥密克戎突破感染未能改善JN.1中和;而接种XBB.1.5适配型疫苗可增强JN.1中和并降低中和失败率。
要点
- 接种三剂原始mRNA疫苗后,健康人、抗TNF组和非抗TNF组JN.1中和水平均低于野生型,多数个体缺乏JN.1中和。
- 抗TNF治疗与低水平抗JN.1-RBD IgG强相关(倍数变化0.48,95%CI 0.39-0.59)。
- 既往奥密克戎突破感染未改善JN.1中和,中和失败率仍为100%;XBB.1.5适配型疫苗可增强JN.1中和并降低中和失败率。
核心结论
- 仅变异株适配型疫苗可针对新出现的SARS-CoV-2变异株提供保护。
- 近期未接种疫苗的炎症性肠病患者和健康个体可能缺乏对JN.1亚变异株KP.3的保护,该亚变异株正引起当前COVID-19病例激增。
研究设计与样本
- 研究利用两个纵向队列,评估原始疫苗(炎症性肠病:n=98;健康人:n=48)、奥密克戎突破感染(炎症性肠病:n=55;健康人:n=57)或XBB.1.5适配型疫苗(炎症性肠病:n=18)诱导的针对JN.1的免疫。
- 采用多重免疫分析方法评估针对野生型SARS-CoV-2和JN.1的中和抗体及抗受体结合域(RBD)IgG水平。
- 主要结局为接种三剂原始mRNA疫苗后按免疫抑制治疗分层的野生型和JN.1中和能力;次要结局为第三剂突破感染或第四剂XBB.1.5适配型mRNA疫苗后的JN.1中和能力。
主要发现
- 接种原始疫苗后,所有研究组(健康人、抗TNF组和非抗TNF组)的JN.1中和水平均低于野生型中和水平(每组p<0.001)。
- 接种原始疫苗后,多数个体缺乏JN.1中和能力(健康人:97.9%;抗TNF组:98.3%;非抗TNF组:92.3%)。
- 经混杂因素调整的多变量模型显示,抗TNF治疗与低水平抗JN.1-RBD IgG强相关(倍数变化0.48,95%CI 0.39-0.59)。
- 有无突破感染患者的JN.1中和能力相似(抗TNF组和非抗TNF组,每组p>0.05);尽管发生突破感染,中和失败率仍为100%。
- XBB.1.5适配型疫苗增强炎症性肠病患者对JN.1的中和(p<0.001),并降低中和失败率(接种前94.4% vs 接种后44.4%;p=0.003)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Variant-adapted COVID-19 vaccines are recommended for patients with inflammatory bowel disease (IBD). However, many patients rely on pre-existing immunity by original vaccines or prior infections. AIM: To assess whether such immunity sufficiently combats the highly immune-evasive SARS-CoV-2 JN.1 variant. METHODS: Utilising two longitudinal cohorts, we evaluated immunity against JN.1 induced by original vaccines (IBD: n = 98; healthy: n = 48), omicron breakthrough infection (IBD: n = 55; healthy: n = 57) or XBB.1.5-adapted vaccines (IBD: n = 18). Neutralisation and anti-receptor-binding domain (RBD) IgG levels against wild-type SARS-CoV-2 and JN.1 were assessed using multiplex immunoassays. Study outcomes were wild-type and JN.1 neutralisation following three doses of original mRNA vaccines, stratified by immunosuppressive therapy (primary outcome), and JN.1 neutralisation following third-dose breakthrough infection or a fourth dose of XBB.1.5-adapted mRNA vaccines (secondary outcomes). RESULTS: Following original vaccines, JN.1 neutralisation was lower than wild-type neutralisation in all study groups (healthy, anti-TNF and non-anti-TNF; each p < 0.001); most individuals lacked JN.1 neutralisation (healthy: 97.9%; anti-TNF: 98.3% and non-anti-TNF: 92.3%). Confounder-adjusted multivariable modelling strongly associated anti-TNF therapy with low levels of anti-JN.1-RBD IgG (fold-change 0.48 [95% CI 0.39-0.59]). JN.1 neutralisation was similar in patients with or without breakthrough infection (anti-TNF, non-anti-TNF; each p > 0.05); neutralisation failure was 100% despite breakthrough infection. XBB.1.5-adapted vaccines enhanced JN.1 neutralisation (p < 0.001) and reduced neutralisation failure rates in patients with IBD (94.4% pre-vaccination vs. 44.4% post-vaccination; p = 0.003). CONCLUSIONS: Only variant-adapted vaccines protect against emerging SARS-CoV-2 variants. Patients with IBD and healthy individuals without recent vaccination may lack protection against the JN.1 subvariant KP.3 which causes current COVID-19 surges.
引用
- Woelfel S, Dütschler J, Junker D, et al. XBB.1.5-Adapted COVID-19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS-CoV-2 JN.1 Variant in Patients With Inflammatory Bowel Disease. Aliment Pharmacol Ther. 2024. PMID: 39468971. doi:10.1111/apt.18349
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。